Latest From Olympus Corp.
For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?
After a study earlier this year found that fixed endcap duodenoscopes continued to pose a significant risk of infecting patients after being washed, the US agency is now urging providers to switch to newer-designed scopes that reduce or eliminate the risk from reprocessing, such as duodenoscopes that have interchangeable caps. The directive from the FDA is good news for Boston Scientific, which makes a disposable duodenoscope that is close to being approved by the agency.
The global market for endoscopic and pelvic surgery procedures is expected to reach $17.7bn in 2023, a CAGR of 6.4%, driven by patients' demand for less invasive surgeries and physicians' preference for minimally invasive surgeries versus open surgeries. By 2023, the number of general and pelvic endoscopic procedures performed globally will reach about 29.7 million, representing a CAGR of 3.6%.
- Medical Devices
- Therapeutic Areas
- Olympus Optical Co. Ltd.
- Pacific Rim
- Parent & Subsidiaries
- Certiman GMBH
- Gyrus Group PLC
- Human Group
- Olympus America Inc.
- Olympus Clinical Instruments Division
- Olympus Corp. of the Americas
- Olympus Medical Systems Group
- Olympus Optical Co. GMBH
- Senior Management
- Hiroyuki Sasa, Pres.
- Contact Info
Phone: (81) 3340 2111
Shinjuku Monolith, 3-1 Nishi-Shinjuku
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.